Eli Wallace

1.0k total citations
16 papers, 697 citations indexed

About

Eli Wallace is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eli Wallace has authored 16 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eli Wallace's work include Microtubule and mitosis dynamics (4 papers), Melanoma and MAPK Pathways (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Eli Wallace is often cited by papers focused on Microtubule and mitosis dynamics (4 papers), Melanoma and MAPK Pathways (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Eli Wallace collaborates with scholars based in United States, Canada and United Kingdom. Eli Wallace's co-authors include Kevin M. Koch, Tammie C. Yeh, Stefan Groß, James D. Winkler, Patrice A. Lee, Brian Hurley, Allison Marlow, Joe Lyssikatos, Vivienne Marsh and Darin Smith and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Eli Wallace

15 papers receiving 679 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eli Wallace United States	9	538	296	111	106	67	16	697
Kelly E. Fisher United States	4	434 0.8×	288 1.0×	91 0.8×	76 0.7×	80 1.2×	6	599
Heidi Simmons United States	4	446 0.8×	296 1.0×	87 0.8×	64 0.6×	57 0.9×	11	596
Arthur Groy United States	6	497 0.9×	279 0.9×	109 1.0×	122 1.2×	78 1.2×	7	696
Allison Marlow United States	3	724 1.3×	447 1.5×	166 1.5×	137 1.3×	80 1.2×	3	946
Ruediger Rueger Switzerland	9	500 0.9×	422 1.4×	98 0.9×	215 2.0×	93 1.4×	12	769
Zoi Karoulia United States	6	560 1.0×	238 0.8×	130 1.2×	85 0.8×	58 0.9×	9	664
Joe Lyssikatos United States	6	380 0.7×	207 0.7×	87 0.8×	80 0.8×	36 0.5×	8	502
Mary J. C. Ludlam United States	6	673 1.3×	259 0.9×	70 0.6×	48 0.5×	66 1.0×	8	937
Tammie C. Yeh United States	11	614 1.1×	503 1.7×	115 1.0×	234 2.2×	75 1.1×	21	1.0k
Yogindra Persaud United States	6	619 1.2×	368 1.2×	136 1.2×	151 1.4×	99 1.5×	12	818

Countries citing papers authored by Eli Wallace

Since Specialization

Citations

This map shows the geographic impact of Eli Wallace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli Wallace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli Wallace more than expected).

Fields of papers citing papers by Eli Wallace

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eli Wallace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli Wallace. The network helps show where Eli Wallace may publish in the future.

Co-authorship network of co-authors of Eli Wallace

This figure shows the co-authorship network connecting the top 25 collaborators of Eli Wallace. A scholar is included among the top collaborators of Eli Wallace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eli Wallace. Eli Wallace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Sharma, Alok K., Jun Pei, Yue Yang, et al.. (2024). Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR. Journal of Biological Chemistry. 300(2). 105650–105650. 11 indexed citations

Stice, James P., Yuting Sun, Nancy E. Kohl, et al.. (2021). Abstract P207: BBP-398, a potent, small molecule inhibitor of SHP2, enhances the response of established NSCLC xenografts to KRASG12C and mutEGFR inhibitors. Molecular Cancer Therapeutics. 20(12_Supplement). P207–P207. 8 indexed citations

Courtney, Kevin D., Jeffrey R. Infante, Elaine T. Lam, et al.. (2016). A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.. Journal of Clinical Oncology. 34(15_suppl). 2506–2506. 5 indexed citations

Han, Guangzhou, Christina Stevens, Zhaodan Cao, et al.. (2016). Abstract 4022: PT2385, a novel HIF-2α antagonist, combines with checkpoint inhibitor antibodies to inhibit tumor growth in preclinical models by modulating myeloid cells and enhancing T cell infiltration. Cancer Research. 76(14_Supplement). 4022–4022. 5 indexed citations

Davies, Kurtis D., P. LouAnn Cable, Jennifer Garrus, et al.. (2011). Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Cancer Biology & Therapy. 12(9). 788–796. 67 indexed citations

Davies, Kurtis D., Michael Humphries, Francis X. Sullivan, et al.. (2011). Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 19(7). 349–363. 22 indexed citations

Moulder, Stacy L., Tara Baetz, Virginia F. Borges, et al.. (2011). Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation.. Molecular Cancer Therapeutics. 10(11_Supplement). A143–A143. 3 indexed citations

Lee, Patrice A., Eli Wallace, Allison Marlow, et al.. (2010). Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor. Cancer Research. 70(8_Supplement). 2515–2515. 28 indexed citations

Bouhana, Karyn, Deborah Anderson, Jennifer Garrus, et al.. (2009). Abstract #1795: In Vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2.. Cancer Research. 69. 1795–1795. 20 indexed citations

10.

Bouhana, Karyn, Rich Woessner, Ira von Carlowitz, et al.. (2008). Differential activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 compared to lapatanib in in vivo xenograft models. Cancer Research. 68. 4848–4848.

11.

Yeh, Tammie C., Vivienne Marsh, Bryan A. Bernat, et al.. (2007). Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor. Clinical Cancer Research. 13(5). 1576–1583. 442 indexed citations

12.

Woessner, Richard, Shelley Allen, Qian Zhao, et al.. (2007). ARRY-520, a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors. Cancer Research. 67. 1433–1433. 9 indexed citations

13.

Lemieux, Christine, Eli Wallace, Rich Woessner, et al.. (2006). ARRY-429520, a Novel KSP Inhibitor with Potent Anti-Proliferative Activity in Leukemic Cell Lines.. Blood. 108(11). 4401–4401. 1 indexed citations

14.

Wallace, Eli, Joseph P. Lyssikatos, Tammie C. Yeh, James D. Winkler, & Kevin M. Koch. (2005). Progress Towards Therapeutic Small Molecule MEK Inhibitors for Use in Cancer Therapy. Current Topics in Medicinal Chemistry. 5(2). 215–229. 56 indexed citations

15.

Satoh, Yoshitaka, et al.. (1998). Synthesis of tetrazole analogs of α-amino acids by alkylation of a Schiff base of α-aminomethyltetrazole. Tetrahedron Letters. 39(21). 3367–3370. 8 indexed citations

16.

Sellwood, R A, S. W. A. Kuper, J I Burn, & Eli Wallace. (1964). Circulating Cancer Cells. BMJ. 1(5399). 1683–1686. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact